Another more recent multicentric study that only included patients with advanced NSCLC and PD-L1 ≥ 50% that received pembrolizumab monotherapy in a first-line setting, as was the case with our cohort, reported a near-identical prevalence of ECOG PS ≥ 2 patients of 20.2% [21]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.